KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis.
Rabara, D., Tran, T.H., Dharmaiah, S., Stephens, R.M., McCormick, F., Simanshu, D.K., Holderfield, M.(2019) Proc Natl Acad Sci U S A 116: 22122-22131
- PubMed: 31611389 
- DOI: 10.1073/pnas.1908353116
- Primary Citation of Related Structures:  
6OB2, 6OB3 - PubMed Abstract: 
KRAS mutations occur in ∼35% of colorectal cancers and promote tumor growth by constitutively activating the mitogen-activated protein kinase (MAPK) pathway. KRAS mutations at codons 12, 13, or 61 are thought to prevent GAP protein-stimulated GTP hydrolysis and render KRAS -mutated colorectal cancers unresponsive to epidermal growth factor receptor (EGFR) inhibitors ...